Axitinib

Phase 2Active

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Pheochromocytoma

Conditions

Pheochromocytoma, Paraganglioma

Trial Timeline

Jan 22, 2019 → Feb 1, 2027

NCT ID

NCT03839498

About Axitinib

Axitinib is a phase 2 stage product being developed by Pfizer for Pheochromocytoma. The current trial status is active. This product is registered under clinical trial identifier NCT03839498. Target conditions include Pheochromocytoma, Paraganglioma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (15)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03839498	Phase 2	Active	Jan 22, 2019	Feb 1, 2027	Pheochromocytoma
NCT02156895	Pre-clinical	Completed	Jul 17, 2018	Aug 6, 2021	Advanced Renal Cell Carcinoma
NCT01798446	Phase 2	Completed	Feb 1, 2013	Dec 1, 2016	Renal Cell Carcinoma
NCT01693822	Phase 2	Completed	Oct 1, 2012	Feb 28, 2022	Clear-cell Metastatic Renal Cell Carcinoma
NCT01649180	Phase 2	Terminated	Jul 1, 2012	Mar 1, 2016	Renal Cell Carcinoma
NCT01540526	Phase 1	Completed	Mar 1, 2012	Dec 1, 2014	Solid Malignancies
NCT01473043	Pre-clinical	Completed	Mar 1, 2012	Mar 1, 2014	Renal Cell Carcinoma
NCT02597322	Phase 2	Completed	Feb 1, 2012	Jun 1, 2017	cT2a N0NxM0 Renal Tumor
NCT01321437	Phase 2	Completed	Dec 1, 2011	Dec 1, 2016	Melanoma
NCT01435122	Phase 2	Completed	Oct 25, 2011	Feb 13, 2018	Carcinoid Tumor
NCT01508117	Phase 2	Terminated	Aug 1, 2011	Oct 1, 2012	Glioblastoma Multiforme
NCT01263769	Phase 2	Completed	Feb 1, 2011	Jun 5, 2023	Kidney Cancer
NCT01255137	Phase 2	Completed	Sep 1, 2010	Dec 1, 2012	Adrenal Cortex Neoplasms
NCT01140737	Phase 2	Completed	Aug 31, 2010	Jan 8, 2019	Soft Tissue Sarcoma
NCT00094094	Phase 2	Completed	Feb 1, 2005	Jul 1, 2007	Lung Neoplasms

Competing Products

4 competing products in Pheochromocytoma

See all competitors

Product	Company	Stage	Hype Score
Anlotinib and Benmelstobart	Sun Pharmaceutical	Phase 2	52
Belzutifan	Merck	Phase 2	52
ONC206 + ONC206: Dose 1 + ONC206: Dose 2	Jazz Pharmaceuticals	Phase 2	49
Phenoxybenzamine + Doxazosin	Atrium Therapeutics	Approved	77

Other Products from Pfizer